Zev Sohn
Hoofd Techniek/Wetenschap/O&O bij TransPharma Medical Ltd.
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Yossi Gross | M | 77 |
TransPharma Medical Ltd.
 TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | 24 jaar |
| Larry Ellberger | M | 76 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Ronit Bendori | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Giora Arbel | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Judith Kornfeld | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Mario Thomas | M | 73 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Jason Martin | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Hana Gadassi | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Yael Kenan | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Ronit Nahary | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Ruth Alon | F | 71 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Galit Levin | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
| Patricia Mosser | F | 68 |
The Trustees of Columbia University in The City of New York
| 38 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| John F. Doorish | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Stephen Peter Hickey | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Karl S. Okamoto | M | 61 |
The Trustees of Columbia University in The City of New York
| 7 jaar |
| Jui Lim | M | - |
The Trustees of Columbia University in The City of New York
| 8 jaar |
| Kyle Loudermilk | M | - |
The Trustees of Columbia University in The City of New York
| 5 jaar |
| In-Joon Kim | M | 75 |
The Trustees of Columbia University in The City of New York
| 7 jaar |
| Jay B. Horowitz | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Max Holmes | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| E. Walter van Valkenburg | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Timothy R. G. Ross | M | - |
The Trustees of Columbia University in The City of New York
| 8 jaar |
| Praveen Krishna Mehrotra | M | - |
The Trustees of Columbia University in The City of New York
| 5 jaar |
| Duke S. Shin | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Kee Yu Tak | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| James Stone | M | - |
The Trustees of Columbia University in The City of New York
| 10 jaar |
| Nasser S. Barghouti | M | 60 |
The Trustees of Columbia University in The City of New York
| 6 jaar |
| Douglas Lindgren | M | - |
The Trustees of Columbia University in The City of New York
| 7 jaar |
| Willie E. Dennis | M | - |
The Trustees of Columbia University in The City of New York
| 8 jaar |
| David Schwartz | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Edieal Pinker | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Philip Nevinny | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Patrick Albrand | M | 68 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Seong-Soo Go | M | 60 |
The Trustees of Columbia University in The City of New York
| 1 jaar |
| Kevin Wong | M | 55 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Frank Peter Seminara | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Kimberly Nelson | F | 61 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Amin Majidi | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Peter M. Cleveland | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Elizabeth Wang | F | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Henry L. King | M | - |
The Trustees of Columbia University in The City of New York
| 12 jaar |
| Alvi Abuaf | M | - |
The Trustees of Columbia University in The City of New York
| 1 jaar |
| Umberto Mosetti | M | 59 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Matt Gonzalez | M | 59 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Kohei Ogawa | M | 67 |
The Trustees of Columbia University in The City of New York
| 1 jaar |
| David B. Barry | M | 59 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Stephen Rand Stonberg | M | 56 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Mark Knackstedt | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Daniel Tsiddon | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Jason Sippel | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Peter F. McLaughlin | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Brad Swanson | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Jacqueline Corbelli | F | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Gilbert Greenman | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Richard L. Maimon | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Fred Stattman | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Daniel von Moos | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Howard Mergelkamp | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Nicholas A. Gravante | M | 63 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Ernest S. Wechsler | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Albert Rabil | M | 61 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Andrew L. Anker | M | 58 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Jeff Klein | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Brian Murphy | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Mark Fielding Bregman | M | 67 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Michael P. Lustig | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Daniel Lew | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Judy Blumstock | F | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| David Chan | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Yale Mitchell Fergang | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Kevin Francis Murphy | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Neil Kochen | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Brian Flynn | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Kevin Toner | M | 60 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Julius Genachowski | M | 61 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Helene L. Kaplan | F | 90 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| William Mundell | M | - |
The Trustees of Columbia University in The City of New York
| 1 jaar |
| Geoffrey Kalish | M | 60 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Jacobus Petrus Bekker | M | 71 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Scott H. Heekin-Canedy | M | 72 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| John Schauerman | M | 67 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Joon-Ho Hahm | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Byung Joon Han | M | 64 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Oded Sarig | M | 68 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Shyam K. Kumaria | M | 74 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Laura A. Smoliar | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Robert Kramer | M | - |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Philip R. Weingold | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Frank A. Segall | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Nick Smirensky | M | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Harry Ballan | M | - |
The Trustees of Columbia University in The City of New York
| 5 jaar |
| Jonathan A. Schaffzin | M | 64 |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Stuart Schear | M | - |
The Trustees of Columbia University in The City of New York
| 1 jaar |
| Henry Mayorga | M | - |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| Jill R. Sanford | F | - |
The Trustees of Columbia University in The City of New York
| 3 jaar |
| Robert H. Mullen | M | 71 |
The Trustees of Columbia University in The City of New York
| 2 jaar |
| Douglas Cifu | M | 58 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| John Joseph Vaske | M | 58 |
The Trustees of Columbia University in The City of New York
| 4 jaar |
| SINGH RAVI | M | - |
The Trustees of Columbia University in The City of New York
| 5 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 88 | 88.00% |
| Israël | 12 | 12.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
